Obesity trials recruiting in Oklahoma

All Obesity trials nationally

Cities in Oklahoma

Recruiting trials in Oklahoma

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Tulsa
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Norman, Oklahoma City, Tulsa
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Norman
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Oklahoma: Moore, Tulsa, Yukon
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Oklahoma: Norman
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Edmond
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Tulsa
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Tulsa
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Oklahoma: Norman, Oklahoma City
• Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
  NCT06488781 · Phase: Phase 2 · Ages: 15 Years to 45 Years · Sex: Female · Oklahoma: Oklahoma City
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Oklahoma: Moore
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Tulsa
• Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
  NCT07282743 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Norman
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Chickasha
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Chickasha
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Oklahoma: Chickasha, Oklahoma City
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Oklahoma: Norman
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Oklahoma: Norman
• Impact of Semaglutide on Tobacco Use and Related Health Behaviors
  NCT06986993 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
  NCT05124808 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 45 Years · Sex: Female · Oklahoma: Norman
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Phentermine's Impact on Treatment in Teens
  NCT07282340 · Phase: Phase 2 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Postnatal Exercise to Activate Baby's Brown Fat
  NCT07467694 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 45 Years · Sex: Female · Oklahoma: Oklahoma City
• The Interaction of Body Composition, Sex Hormones and Exercise in Men
  NCT06970457 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 79 Years · Sex: Male · Oklahoma: Stillwater
• Uterine Preservation Via Lifestyle Transformation
  NCT05903131 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · Oklahoma: Oklahoma City
• Wakaya: Rising Up for Choctaw Youth Health
  NCT05818384 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 19 Years · Sex: All (male and female) · Oklahoma: Durant
• iAmHealthy Clinical Practice Guideline (CPG)
  NCT06888011 · Phase: Not applicable (e.g. observational or device study) · Ages: 6 Years to 11 Years · Sex: All (male and female) · Oklahoma: Oklahoma City